Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + Capecitabine in Advanced Cholangiocarcinoma
NCT00084942Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Oct 2002
- Primary completion
- May 2004
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and capecitabine in cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Response Rate. Started Oct 2002; status: completed.
02
Drugs
gemcitabinecapecitabine
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NCT00084942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084942.